Last reviewed · How we verify
Lenvatinib 20mg — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Lenvatinib 20mg (Lenvatinib 20mg) — National Cancer Center Hospital East.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lenvatinib 20mg TARGET | Lenvatinib 20mg | National Cancer Center Hospital East | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lenvatinib 20mg CI watch — RSS
- Lenvatinib 20mg CI watch — Atom
- Lenvatinib 20mg CI watch — JSON
- Lenvatinib 20mg alone — RSS
Cite this brief
Drug Landscape (2026). Lenvatinib 20mg — Competitive Intelligence Brief. https://druglandscape.com/ci/lenvatinib-20mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing